Originally posted on Facebook. How can digital help in the fight against malaria? Bertrand Bodson, our Chief Digital Officer, shares his own experience of malaria as a teenager and a vision for the role of data and digital. #MalariaFuture #WorldMosquitoDay
Tag: Malaria
Archived: Bayer Announces WHO Pre-Qualification for Fludora Fusion to Combat Malaria
The recent WHO Malaria Report 2018 flagged another stalling in the progress towards elimination of the disease, in part due to development of insecticide resistance in vector mosquitoes to current preventative solutions. There is therefore an urgent need to maintain investment into innovation for malaria vector control; to develop new…
Archived: Novartis: Meet Martin Grobusch, Malaria Fighter
Over the last 15 years, huge progress has been made in the fight against malaria, with the number of people dying from the disease dropping by almost two-thirds.1 Yet signs of resistance to existing antimalarial drugs are a rising concern, and the search is on for a replacement. Martin Grobusch…
Archived: Researchers Overcome Hurdles to Test Experimental Malaria Drug
(Originally published on Novartis.com) Dr. Bakary Fofana and two colleagues sit at a desk in a health clinic and research lab in southern Mali, writing an email to their collaborators in the United States. Two pre-labeled test tubes for patient blood samples broke during the three-week transit from the US…
Archived: Novartis: Together We Can End Malaria for Good
Novartis (No. 2 on the DiversityInc Top 50 Companies list) isproud of the passion of itspeople and their dedication to the fight against malaria.
Archived: Experimental Treatment Clears Malaria Infections in Novartis Small Clinical Study
In a remote village in Thailand, on the border of Myanmar (formerly Burma), Novartis (No. 2 on the DiversityInc Top 50 Companies list) researchers completed an early-phase clinical trial of an experimental treatment for malaria. The team overcame floods that swamped the facility an open-air structure with wooden beds and…
Archived: Novel Novartis Malaria Compound Shows Potential to be Effective Against Infections Resistant to Antimalarial Drugs
Novartis (No. 2 on the DiversityInc Top 50 Companies list) published proof of concept study results in the New England Journal of Medicine showing that its new antimalarial compound, KAF156, demonstrated activity against both vivax and falciparum malaria, including artemisinin-resistant parasites. Malaria is a life-threatening disease primarily caused by parasites…